Respiratory Medicine
Volume 104, Issue 10 , Pages 1391-1395 , October 2010

Involvement of type II pneumocytes in the pathogenesis of chronic obstructive pulmonary disease

  • Chun-zhen Zhao

      Affiliations

    • Zhejiang Respiratory Drugs Research Laboratory of State Food and Drugs Administration of China, College of Medical Sciences, Zhejiang University, China
    • ,
  • Xiao-cong Fang

      Affiliations

    • Zhejiang Respiratory Drugs Research Laboratory of State Food and Drugs Administration of China, College of Medical Sciences, Zhejiang University, China
    • Department of Respiratory Medicine, Zhongshan Hospital, Fudan University, China
    • ,
  • Diane Wang

      Affiliations

    • Zhejiang Respiratory Drugs Research Laboratory of State Food and Drugs Administration of China, College of Medical Sciences, Zhejiang University, China
    • ,
  • Fa-di Tang

      Affiliations

    • Zhejiang Respiratory Drugs Research Laboratory of State Food and Drugs Administration of China, College of Medical Sciences, Zhejiang University, China
    • Corresponding Author InformationCorresponding author. Tel.: +86 46 46 125 931.
    • ,
  • Xiang-dong Wang

      Affiliations

    • Zhejiang Respiratory Drugs Research Laboratory of State Food and Drugs Administration of China, College of Medical Sciences, Zhejiang University, China
    • Department of Respiratory Medicine, Zhongshan Hospital, Fudan University, China
    • Corresponding Author InformationCorresponding author. Zhejiang Respiratory Drugs Research Laboratory of State Food and Drugs Administration of China, College of Medical Sciences, Zhejiang University, China

Received 31 January 2010 ,Accepted 25 June 2010.

References 

  1. Cazzola M, Donner CF, Hanania NA. One hundred years of chronic obstructive pulmonary disease (COPD). Respir Med. 2007;101(6):1049–1065Devendra G, Spragg RG. Lung surfactant in subacute pulmonary disease. Respir Res. 2002;3:19
  2. Demedts IK, Demoor T, Bracke KR, Joos GF, Brusselle GG. Role of apoptosis in the pathogenesis of COPD and pulmonary emphysema. Respir Res. 2006;30(7):53
  3. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645–2653
  4. Tetley TD. Inflammatory cells and chronic obstructive pulmonary disease. Curr Drug Targets Inflamm Allergy. 2005 Dec;4(6):607–618
  5. Zhao MQ, Amir MK, Rice WR, Enelow RI. Type II pneumocyte-CD8 + T-cell interactions: relationship between target cell cytotoxicity and activation. Am J Respir Cell Mol Biol. 2001;25:362–369
  6. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med. 2000;343:269–280
  7. Serrano-Mollar A, Nacher M, Gay-Jordi G. Intratracheal transplantation of alveolar type II cells reverses bleomycin-induced lung fibrosis. Am J Respir Crit Care Med. 2007;176(12):1261–1268
  8. Devendra G, Spragg RG. Lung surfactant in subacute pulmonary disease. Respir Res. 2002;3:19
  9. Xue Y, Williams TL, Li T, et al. Type II pneumocytes modulate surfactant production in response to cigarette smoke constituents: restoration by vitamins A and E. Toxicol In Vitro. 2005;19(8):1061–1069
  10. Wirtz HR, Schmidt M. Acute influence of cigarette smoke on secretion of pulmonary surfactant in rat alveolar type II cells in culture. Eur Respir J. 1996 Jan;9(1):24–32
  11. Vlachaki EM, Koutsopoulos AV, Tzanakis N, et al. Altered surfactant protein-A expression in type II pneumocytes in COPD. Chest. 2010;137(1):37–45
  12. Dwyer TM. Cigarette smoke-induced airway inflammation as sampled by the expired breath condensate. Am J Med Sci. 2003 Oct;326(4):174–178
  13. Cox RA, Burke AS, Jacob S, et al. Activated nuclear factor kappa B and airway inflammation after smoke inhalation and burn injury in sheep. J Burn Care Res. 2009;30(3):489–498
  14. Demkow U. The oxidative stress in emphysema and chronic obstructive pulmonary disaease (COPD). Cent Eur J Immunol. 2009;34(2):143–146
  15. Vernooy J, Drummen N, van Suylen RJ, et al. Enhanced pulmonary leptin expression in patients with severe COPD and asymptomatic smokers. Thorax. 2009;64(1):26–32
  16. McCourtie AS, Farivar AS, Woolley SM, et al. Alveolar macrophage secretory products effect type 2 pneumocytes undergoing hypoxia-reoxygenation. Ann Thorac Surg. 2008;86(6):1774–1780
  17. Maestrelli P, Paska C, Saetta M, et al. Decreased haem oxygenase-1 and increased inducible nitric oxide synthase in the lung of severe COPD patients. Eur Respir J. 2003;21(6):971–976
  18. Hodge S, Hodge G, Holmes M, Reynolds PN. Increased airway epithelial and T-cell apoptosis in COPD remains despite smoking cessation. Eur Respir J. 2005;25(3):447–454
  19. Vernooy JH, Dentener MA, van Suylen RJ, et al. Intratracheal instillation of lipopolysaccharide in mice induces apoptosis in bronchial epithelial cells: no role for tumor necrosis factor-alpha and infiltrating neutrophils. Am J Respir Cell Mol Biol. 2001;24(5):569–576
  20. Cataldo DD, Gueders MM, Rocks N, et al. Pathogenic role of matrix metalloproteases and their inhibitors in asthma and chronic obstructive pulmonary disease and therapeutic relevance of matrix metalloproteases inhibitors. Cell Mol Biol. 2003;49(6):875–884
  21. De Boer WI, van Schadewijk A, Sont JK, et al. Transforming growth factor beta1 and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;158:1951–1957
  22. Takizawa H, Tanaka M, Takami K, et al. Increased expression of transforming growth factor-beta1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med. 2001;163:1476–1483
  23. Serrano-Mollar A, Nacher M, Gay-Jordi G, et al. Intratracheal transplantation of alveolar type II cells reverses bleomycin-induced lung fibrosis. Am J Resp Crit Care. 2007;176(12):1261–1268
  24. Frerking I, Günther A, Seeger W, Pison U. Pulmonary surfactant: functions, abnormalities and therapeutic options. Intensive Care Med. 2001 Nov;27(11):1699–1717
  25. Pastva AM, Wright JR, Williams KL. Immunomodulatory roles of surfactant proteins A and D: implications in lung disease. Proc Am Thorac Soc. 2007;4(3):252–257
  26. Nogee LM. Genetic mechanisms of surfactant deficiency. Biol Neonate. 2004;85:314–318
  27. Devendra G, Spragg RG. Lung surfactant in subacute pulmonary disease. Respir Res. 2002;3:19
  28. Hohlfeld J, Fabel H, Hamm H. The role of pulmonary surfactant in obstructive airways disease. Eur Respir J. 1997 Feb;10(2):482–491
  29. Hamvas A, Nogee LM, White FV, et al. Progressive lung disease and surfactant dysfunction with a deletion in surfactant protein C gene. Am J Respir Cell Mol Biol. 2004;30(6):771–776
  30. Pison U, Tam EK, Caughey GH, Hawgood S. Proteolytic inactivation of dog lung surfactant-associated proteins by neutrophil elastase. Biochim Biophys Acta. 1989;992:251–257
  31. Putman E, Van Golde LMG, Haagsman HP. Toxic oxidant species and their impact on the pulmonary surfactant system. Lung. 1997;175:75–103
  32. Anseth JW, Goffin AJ, Fuller GG, et al. Lung surfactant gelation induced by epithelial cells exposed to air pollution or oxidative stress. Am J Respir Cell Mol Biol. 2005;33(2):161–168
  33. Starosta V, Griese M. Oxidative damage to surfactant protein D in pulmonary diseases. Free Radic Res. 2006;40(4):419–425
  34. Joppa P, Petrásová D, Stancák B, et al. Oxidative stress in patients with COPD and pulmonary hypertension. Wien Klin Wochenschr. 2007;119(13–14):428–434
  35. Cochrane CG. Pulmonary surfactant in allergic inflammation: new insights into the molecular mechanisms of surfactant function. Am J Physiol Lung Cell Mol Physiol. 2005;288(4):L608–L609
  36. Calkovská A. Pulmonary surfactant in the respiratory tract. Cesk Fysiol. 2000;49(3):145–151
  37. Lusuardi M, Capelli A, Carli S, et al. Role of surfactant in chronic obstructive pulmonary disease: therapeutic implications. Respiration. 1992;59(Suppl. 1):28–32
  38. Schmekel B, Bos JA, Khan AR, Wohlfart B, Lachmann B, Wollmer P. Integrity of the alveolar-capillary barrier and alveolar surfactant system in smokers. Thorax. 1992;47:603–608
  39. Wirtz HR, Schmidt M. Acute influence of cigarette smoke on secretion of pulmonary surfactant in rat alveolar type II cells in culture. Eur Respir J. 1996;9:24–32
  40. GuoX Lin HM, Lin Z, Montaño M, Sansores R, Wang G, et al. Surfactant protein gene A, B, and D marker alleles in chronic obstructive pulmonary disease of a Mexican population. Eur Respir J. 2001;18:482–490
  41. Hu RC, Xu YJ, Zhang JX. Surfactant protein B 1580 polymorphism is associated with susceptibility to chronic obstructive pulmonary disease in Chinese Han population. J Huazhong Univ Sci Technol. 2004;3:5;[English Abstract]
  42. Sims MW, Tal-Singer RM, Kierstein S, Musani AI, Beers MF, Panettieri RA, et al. Chronic obstructive pulmonary disease and inhaled steroids alter surfactant protein D (SP-D) levels: a cross-sectional study. Respir Res. 2008;9(1):13
  43. Kierstein S, Poulain FR, Cao Y, Grous M, Mathias R, Kierstein G, et al. Susceptibility to ozone-induced airway inflammation is associated with decreased levels of surfactant protein D. Respir Res. 2006;7(1):85
  44. Wert SE, Yoshida M, LeVine AM, et al. Increased metalloproteinase activity, oxidant production, and emphysema in surfactant protein D gene-inactivated mice. Proc Natl Acad Sci U S A. 2000;97(11):5972–5977
  45. Yoshida M, Whitsett JA. Alveolar macrophages and emphysema in surfactant protein-D-deficient mice. Respirology. 2006;11(Suppl. 1):S37–S40
  46. Haque R, Umstead TM, Ponnuru P, et al. Role of surfactant protein-A (SP-A) in lung injury in response to acute ozone exposure of SP-A deficient mice. Toxicol Appl Pharmacol. 2007;220(1):72–82
  47. Hirama N, Shibata Y, Otake K, et al. Increased surfactant protein-D and foamy macrophages in smoking-induced mouse emphysema. Respirology. 2007;12(2):191–201
  48. Enhorning G, Duffy LC, Welliver RC. Pulmonary surfactant maintains patency of conducting airways in the rat. Am J Respir Crit Care Med. 1995;151(2 Pt 1):554–556
  49. Kerecman J, Mustafa SB, Vasquez MM, et al. Immunosuppressive properties of surfactant in alveolar macrophage NR8383. Inflamm Res. 2008;57(3):118–125

  50. Surfactant protein D regulates NF-kB and matrix metalloproteinase production in alveolar macrophages via oxidant-sensitive pathways

  51. Anzueto A, Jubran A, Ohar JA, et al. Effects ofaerosolized surfactant in patients with stable chronic bronchitis: a prospective randomized controlled trial. JAMA. 1997;278:1426–1431
  52. Wirtz H, Habscheid W, Ertl G, et al. Exogenous surfactant application in respiratory failure due to chronic obstructive pulmonary disease. Respiration. 1995;62(3):157–159
  53. Chrysofakis G, Tzanakis N, Kyriakoy D, et al. Perforin expression and cytotoxic activity of sputum CD8+ lymphocytes in patients with COPD. Chest. 2004;125(1):71–76
  54. Vernooy JH, Möller GM, van Suylen RJ, et al. Increased granzyme A expression in type II pneumocytes of patients with severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(5):464–472
  55. Sower LE, Klimpel GR, Hanna W, Froelich CJ. Extracellular activities of human granzymes. Granzyme A induces IL-6 and IL-8 production in fibroblast and epithelial cell lines. Cell Immunol. 1996;171(1):159–163
  56. Buzza MS, Zamurs L, Sun J, et al. Extracellular matrix remodeling by human granzyme B via cleavage of vitronectin, fibronectin, and laminin. J Biol Chem. 2005;280(25):23549–23558
  57. Lieberman J, Fan Z. Nuclear war: the granzyme A-bomb. Curr Opin Immunol. 2003;15(5):553–559
  58. Trapani JA, Sutton VR, Granzyme B. Pro-apoptotic, antiviral and antitumor functions. Curr Opin Immunol. 2003;15(5):533–543

PII: S0954-6111(10)00297-0

doi: 10.1016/j.rmed.2010.06.018

Respiratory Medicine
Volume 104, Issue 10 , Pages 1391-1395 , October 2010

Article Tools

* Image Usage & Resolution